MDXH heeft een heel duidelijke focus en dàt is een must om zich in een wel afgelijnde doelmarkt sterk te kunnen positioneren en om een lean business model te kunnen uitbouwen en in stand houden (communicatie, sales en distributie binnen één kanaal!):
"MDxHealth’s strategy is to become a one-stop shop for the urologist with the capacity to handle any type of specimen (i.e., blood, urine, and tissue)."
Straks hebben we testen voor prostaat (diverse testen), blaas, nieren…met maar één aanspreekpunt: de uroloog.
En wat brengt de toekomst?
MDXH Management ziet 2016 als volgt:
We are very pleased with our progress and expect 2016 to be another very exciting year of growth and accomplishment as we advance our strategic plan to become the leading urological oncology diagnostics company bringing innovative molecular diagnostic tests to the market. The investment we have made and will continue to make in our epigenetic platform and molecular products, the focus on quality, design control and clinical validation, as well as the early success of our ConfirmMDx Prostate Cancer test and progress with our reimbursement strategy[b] is clearly recognized by both the clinical and financial markets.[/b] We believe that we are in the early stages of a sustained growth cycle, with the ultimate goal of offering clinicians a range of complementary molecular tests for the diagnosis, staging and treatment of urological cancers.